Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
Launched by THOMAS JEFFERSON UNIVERSITY · Jul 31, 2025
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best way to manage pain after a cesarean delivery (C-section), which is a common surgery to deliver a baby. After a C-section, many women experience more pain compared to vaginal birth, and managing this pain well is important for both the mother and baby’s health. The study compares two ways of giving common pain medicines—acetaminophen (Tylenol) and non-steroidal anti-inflammatory drugs (NSAIDs, like ibuprofen). Researchers want to find out if giving these medicines at different times (staggered) works better than giving them both at the same time (simultaneous) to reduce pain after surgery.
Women who might be eligible to join this study are those who are at least 34 weeks pregnant with one baby and are planning to have a C-section using regional anesthesia (numbing just the lower half of the body). Women who cannot take acetaminophen or NSAIDs, have used opioids recently or in the past, or have certain medical conditions are not eligible. If you join, you will be randomly assigned to receive the pain medicines either together or spaced apart after your surgery, and the study will monitor how well your pain is controlled. This study is not yet recruiting participants but aims to help improve comfort and recovery after cesarean deliveries in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • \>/= 34 weeks gestation
- • Singleton pregnancy
- • Delivery via cesarean section under regional anesthesia
- Exclusion Criteria:
- • Contraindication to acetaminophen or NSAIDs
- • Current or history of opioid use or misuse
- • Intrauterine fetal demise
- • Major congenital anomaly
- • Conversion to general anesthesia intra-op or planned general anesthesia
- • Mid-line vertical skin incision
- • Receipt of intraoperative local analgesia such as Transversus Abdominis Plan (TAP) block or wound infiltration
About Thomas Jefferson University
Thomas Jefferson University is a distinguished academic institution located in Philadelphia, Pennsylvania, renowned for its commitment to advancing healthcare through research and education. As a clinical trial sponsor, the university leverages its extensive resources and interdisciplinary expertise to conduct innovative research aimed at improving patient outcomes. With a focus on translational medicine, Thomas Jefferson University collaborates with various stakeholders, including healthcare professionals, industry partners, and regulatory agencies, to ensure the highest standards of scientific rigor and ethical conduct in its clinical trials. The institution is dedicated to fostering a culture of excellence in research, ultimately contributing to the advancement of medical knowledge and the development of novel therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported